Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in <scp>CR</scp>-Reference-Cited by-同舟云学术

Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR

Published:2022-12 Issue:2 Volume:110 Page:188-197
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Klyuchnikov Evgeny¹^ORCID,Langebrake Claudia¹²,Badbaran Anita¹,Dadkhah Adrin¹²,Massoud Radwan¹,Freiberger Petra¹,Ayuk Francis¹,Janson Dietlinde¹,Wolschke Christine¹,Bacher Ulrike³,Kröger Nicolaus¹^ORCID

Affiliation:

1. Department of Stem Cell Transplantation, University Medical Center Eppendorf University of Hamburg Hamburg Germany

2. Hospital Pharmacy University Medical Center Hamburg‐Eppendorf Hamburg Germany

3. Department of Hematology and Central Hematology Laboratory, Inselspital Bern University Hospital Bern Switzerland

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13893

Reference52 articles.

1. Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

2. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors;Peters WP;Cancer Res,1987

3. CONVULSIONS DUE TO HIGH-DOSE BUSULPHAN

4. Busulfan bioavailability

5. Risk factors for hepatic veno‐occlusive disease after high‐dose busulfan‐containing regimens followed by autologous bone marrow transplantation: a study in 136 children;Méresse V;Bone Marrow Transplant,1992

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Расчет и коррекция дозы цитостатических препаратов в режимах кондиционирования перед аллоТГСК у пациентов с избытком массы тела или ее дефицитом;Clinical Oncohematology;2024-07-01

3. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients;Therapeutic Drug Monitoring;2024-06-14

4. Population Pharmacokinetic Modeling for Twice-Daily Intravenous Busulfan in a Large Cohort of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation—A 10-Year Single-Center Experience;Pharmaceutics;2023-12-20